| Bayer granted marketing authorisation for antihypertensive drug combination in EU | Posted on 21/04/2008 in Pharmaceutical Company Product News Bayer Schering Pharma has announced that it has been granted marketing authorisation from the European Commission for its new antihypertensive fixed dose combination drug.
It reports that PritorPlus 80/25 and Kinzalkomb 80/25 (80mg telmisartan/25mg hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients whose blood pressure is not controlled adequately by PritorPlus 80/12.5 and Kinzalkomb 80/12.5.
The new combination dose is also indicated in patients whose condition has previously stabilised on telmisartan and hydrochlorthiazide separately at these doses.
Bayer notes that the new formulation of the drug will be launched in Germany by the end of April, with further EU launches following soon.
Dr Rahul Agrawal, global clinical leader of cardiology at Bayer HealthCare, said: "For physicians and patients, it is often very challenging to reach the recommended blood pressure targets with the available treatments."
He added that the new combination of PritorPlus 80/25 and Kinzalkomb 80/25 offers doctors a new therapeutical strategy for the treatment of patients with hypertension.
Earlier this month, Bayer announced the results of its Ontarget trial, with Pritor/Kinzalmono (telmisartan) reportedly showing the same protection as existing cardiovascular drugs while offering increased tolerability.Other news stories from 21/04/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
